Modulation of survivin expression

Details for Australian Patent Application No. 2010202724 (hide)

Owner Isis Pharmaceuticals, Inc.

Inventors Bhat, Balkrishen; Bharvin, Kumar; Swayze, Eric

Agent Spruson & Ferguson

Pub. Number AU-B-2010202724

Parent 2004253455

Filing date 29 June 2010

Wipo publication date 15 July 2010

Acceptance publication date 5 April 2012

International Classifications

C07H 21/04 (2006.01) Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

A61K 48/00 (2006.01) Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases

C12N 15/00 (2006.01) Mutation or genetic engineering

C12N 15/113 (2010.01) Mutation or genetic engineering - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Event Publications

15 July 2010 Application Open to Public Inspection

  Published as AU-B-2010202724

15 July 2010 Complete Application Filed

3 February 2011 Assignment before Grant

  Isis Pharmaceuticals, Inc.; Eli Lilly and Company The application has been assigned to Isis Pharmaceuticals, Inc.

5 April 2012 Application Accepted

  Published as AU-B-2010202724

2 August 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2010202725-Gaming machine with sound effects

2010202723-Improved water heater